Literature DB >> 14514131

Risk of malignancy in an unselected cohort of Icelandic patients with systemic lupus erythematosus.

O Ragnarsson1, G Gröndal, K Steinsson.   

Abstract

In the present literature there is still controversy as to whether patients with systemic lupus erythematosus (SLE) are at increased risk of developing malignant diseases. In recent years a number of epidemiological studies have been conducted and some have suggested an association between SLE and malignant diseases while other studies have not. The objective of this study was to investigate this relationship in an unselected cohort of Icelandic patients with SLE. All patients diagnosed with SLE registered in the Icelandic SLE database were compared to the Icelandic cancer registry. For completeness, hospital charts and outpatient notes were also reviewed. The study period was from 1957 to the end of 2001. The O/E (observed/expected ratio), CI and P-value were calculated for total number of malignancies as well as individual malignancy types. Of 238 patients diagnosed with SLE (213 women and 25 men) 39 malignancies were diagnosed in 36 patients; 32 women and four men. Of the 36 patients, 27 were diagnosed subsequently with SLE and malignant disease. The mean age at diagnosis of SLE was 43.2 years (range 10-81) and at time of diagnosis of malignancy 62.7 years (range 43-86). The O/R for the whole study population was 1.38 (CI 0.89-1.87, P = 0.063), 1.45 for the women (CI 0.91-1.99, P = 0.051) and 1.03 for the men (CI 0.22-2.66, P = 0.560). The O/R for the most frequent malignancies diagnosed subsequently to SLE was 6.43 for squamous cell skin cancer (CI 1.31-18.5, P = 0.012), 5.48 for lymphoma (CI 0.64-19.6, P = 0.052), 2.46 for uterine cancer (CI 0.29-8.78, P = 0.196), 2.0 for ovarian cancer (CI 0.23-7.14, P = 0.264), 1.72 for lung cancer (CI 0.36-4.95, P = 0.254) and 1.6 for breast cancer (CI 0.65-3.23, P = 0.154). The total number of patient-years at risk was 2774 years. The results from this study on an unselected cohort of Icelandic SLE patients do not suggest an overall association between SLE and malignancy. Squamous cell skin cancer was the only individual cancer type that was statistically increased in the population and the numbers for lymphoma were borderline statistically significant.

Entities:  

Mesh:

Year:  2003        PMID: 14514131     DOI: 10.1191/0961203303lu443oa

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  14 in total

Review 1.  Systemic lupus erythematosus, human papillomavirus infection, cervical pre-malignant and malignant lesions: a systematic review.

Authors:  Iuri Usêda Santana; Alline do Nascimento Gomes; Leomar D'Cirqueira Lyrio; Maria Fernanda Rios Grassi; Mittermayer Barreto Santiago
Journal:  Clin Rheumatol       Date:  2010-10-31       Impact factor: 2.980

Review 2.  A review on SLE and malignancy.

Authors:  May Y Choi; Kelsey Flood; Sasha Bernatsky; Rosalind Ramsey-Goldman; Ann E Clarke
Journal:  Best Pract Res Clin Rheumatol       Date:  2017-11-10       Impact factor: 4.098

3.  No association between the risk of breast cancer and systemic lupus erythematosus: evidence from a meta-analysis.

Authors:  Zahra Rezaieyazdi; Samira Tabaei; Yalda Ravanshad; Javad Akhtari; Hassan Mehrad-Majd
Journal:  Clin Rheumatol       Date:  2018-01-02       Impact factor: 2.980

Review 4.  Thyroid cancer in systemic lupus erythematosus: a meta analysis.

Authors:  Min Zhang; Xiao-Mei Li; Guo-Sheng Wang; Long Qian; Jin-Hui Tao; Yan Ma; Xiang-Pei Li
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

5.  Malignancies associated with systemic lupus erythematosus in Taiwan: a nationwide population-based cohort study.

Authors:  Ji-An Liang; Li-Min Sun; Jun-Jun Yeh; Wan-Yu Lin; Shih-Ni Chang; Hung-Chang Sung; Chia-Hung Kao
Journal:  Rheumatol Int       Date:  2010-12-31       Impact factor: 2.631

Review 6.  Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer.

Authors:  Alexis L Franks; Jill E Slansky
Journal:  Anticancer Res       Date:  2012-04       Impact factor: 2.480

Review 7.  A systematic review of the epidemiological literature on the risk of urological cancers in systemic lupus erythematosus.

Authors:  Hou-Bao Huang; Shu-Chuan Jiang; Jie Han; Qing-Shui Cheng; Chang-Bin Dong; Cai-Ming Pan
Journal:  J Cancer Res Clin Oncol       Date:  2014-02-14       Impact factor: 4.553

8.  Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California.

Authors:  Arti Parikh-Patel; Richard H White; Mark Allen; Rosemary Cress
Journal:  Cancer Causes Control       Date:  2008-04-02       Impact factor: 2.506

9.  Lung cancer and interstitial lung diseases: a systematic review.

Authors:  Kostas Archontogeorgis; Paschalis Steiropoulos; Argyris Tzouvelekis; Evangelia Nena; Demosthenes Bouros
Journal:  Pulm Med       Date:  2012-07-29

10.  Incidence of cancer among female patients with systemic lupus erythematosus in Korea.

Authors:  Kwi Young Kang; Hyun Ok Kim; Ho Sung Yoon; Jeniffer Lee; Won Chul Lee; Hyek-Jae Ko; Ji Hyeon Ju; Chul-Soo Cho; Ho-Youn Kim; Sung-Hwan Park
Journal:  Clin Rheumatol       Date:  2009-12-30       Impact factor: 3.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.